Table 2.
Cox regression models results
| Univariable | Multivariable | Stepwise backward selection | |
|---|---|---|---|
| on OS | HR [95%CI], p value |
Full model HR [95%CI], p value |
Reduced model, AIC = 292.2 HR [95%CI], p value |
| Cholesterol (mg/dl) | 0.99 [0.98–0.99], 0.02 | 0.99 [0.98–1.01], 0.417 | Removed |
| ABCA1(%)* | 1.19 [1.09–1.29], < 0.001 | 1.07 [0.93–1.23], 0.326 | Removed |
| ABCG1 (%)* | 1.21 [1.06–1.38], 0.004 | 1.04 [0.91–1.20], 0.561 | Removed |
| Cholesterol PD (%)* | 0.72 [0.64–0.80], < 0.001 | 0.80 [0.69–0.94], 0.005 | 0.77 [0.67–0.89], < 0.001 |
| CLC (μg/mg) | 0.83 [0.77–0.89], < 0.001 | 0.92 [0.83–1.01], 0.09 | 0.92 [0.84–1.01], 0.07 |
| on PFS | HR [95%CI], p value |
Full model HR [95%CI], p value |
Reduced model, AIC = 340.8 HR [95%CI], p value |
| Cholesterol (mg/dl) | 0.99 [0.98–0.99], 0.01 | 0.99 [0.98–1.00], 0.139 | Removed |
| ABCA1 (%)* | 1.12 [1.02–1.23], 0.01 | 1.01 [0.88–1.16], 0.915 | Removed |
| ABCG1 (%)* | 1.19 [1.04–1.36], 0.01 | 1.09 [0.94–1.26], 0.269 | 1.10 [0.96–1.26], 0.167 |
| Cholesterol PD (%)* | 0.80 [0.73–0.88], < 0.001 | 0.85 [0.73–0.97], 0.014 | 0.81 [0.74–0.90], < 0.001 |
| CLC (μg/mg) | 0.88 [0.82–0.94], < 0.001 | 0.98 [0.89–1.07], 0.622 | Removed |
| on CB | OR [95%CI], p value |
Full model OR [95%CI], p value |
Reduced model, AIC = 79.2 OR [95%CI], p value |
| Cholesterol (mg/dl) | 1.02 [1.00–1.03], 0.045 | 1.00 [0.99–1.02], 0.67 | |
| ABCA1 (%)* | 0.82 [0.65–1.00], 0.068 | 1.04 [0.78–1.35], 0.80 | |
| ABCG1 (%)* | 0.67 [0.48–0.88], 0.009 | 0.75 [0.51–1.04], 0.11 | 0.78 [0.55–1.04], 0.12 |
| Cholesterol PD (%)* | 1.31 [1.13–1.57], 0.001 | 1.12 [0.90–1.42], 0.31 | |
| CLC (μg/mg) | 1.30 [1.14–1.54], < 0.001 | 1.16 [0.96–1.46], 0.16 | 1.26 [1.10–1.48], 0.003 |
OS Overall survival, ABCA1 ATP-binding cassette transporter A1, ABCG1 ATP-binding cassette transporter G1, PD Passive diffusion, CLC Cholesterol loading capacity, PFS Progression-free survival, CB Clinical benefit
*% = cholesterol efflux amount/overall cellular cholesterol